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Abstract
Background: People with rheumatoid arthritis (RA) should use DMARDs (disease-modifying anti-
rheumatic drugs) within the first three months of symptoms in order to prevent irreversible joint
damage. However, recent studies report the delay in DMARD use ranges from 6.5 months to 11.5
months in Canada. While most health service delivery interventions are designed to improve the
family physician's ability to refer to a rheumatologist and prescribe treatments, relatively little has
been done to improve the delivery of credible, relevant, and user-friendly information for
individuals to make treatment decisions. To address this care gap, the Animated, Self-serve, Web-
based Research Tool (ANSWER) will be developed and evaluated to assist people in making
decisions about the use of methotrexate, a type of DMARD. The objectives of this project are: 1)
to develop ANSWER for people with early RA; and 2) to assess the extent to which ANSWER
reduces people's decisional conflict about the use of methotrexate, improves their knowledge
about RA, and improves their skills of being 'effective healthcare consumers'.
Methods/design:  Consistent with the International Patient Decision Aid Standards, the
development process of ANSWER will involve: 1.) creating a storyline and scripts based on the best
evidence on the use of methotrexate and other management options in RA, and the contextual
factors that affect a patient's decision to use a treatment as found in ERAHSE; 2.) using an
interactive design methodology to create, test, analyze and refine the ANSWER prototype; 3.)
testing the content and user interface with health professionals and patients; and 4.) conducting a
pilot study with 51 patients, who are diagnosed with RA in the past 12 months, to assess the extent
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to which ANSWER improves the quality of their decisions, knowledge and skills in being effective
consumers.
Discussion: We envision that the ANSWER will help accelerate the dissemination of knowledge
and skills necessary for people with early RA to make informed choices about treatment and to
manage their health. The latest in animation and online technology will ensure ANSWER fills a
knowledge translation gap, focusing on the next generation of people living with RA.
Background
Treatment approaches for RA have changed drastically in
the last decade. In the old "pyramid" approach, patients
were treated with non-steroidal anti-inflammatory drugs
(NSAIDs) without DMARDs until evidence of joint dam-
age appeared. Nowadays, DMARD is used early (i.e.,
within three months of onset) and consistently, with the
aim of eradicating inflammation and preventing joint
damage [1-3]. The short-term clinical efficacy of various
DMARDs at reducing disease activity, improving physical
function and retarding radiographic progression has been
demonstrated in RCTs and the subsequent systematic
reviews [4-6]. Long-term epidemiological studies have
also shown that earlier and more consistent treatment
with DMARDs reduces joint destruction and leads to bet-
ter long-term physical function [7-9]. Delays as brief as
three months in starting DMARDs have been associated
with poorer long-term outcomes, including greater physi-
cal disability [10-12] and joint damage [13-15], and less
chance of remission [16]. The evidence suggests that there
is a window of opportunity, early in the disease, to suc-
cessfully control the disease progression; however, only a
minority of people with RA used DMARDs after a recent
diagnosis [17].
Patients' decisions on medication use can be affected by
their concerns about side effects [18]. For example, with
methotrexate, a commonly used DMARD, the side effects
may include diarrhoea, lung infections, headache, nausea,
heartburn, rash, and high liver enzyme, although the
occurrence is rare [4,5]. About 10% of patients stopped
taking methotrexate due to side effects; however, 9% also
stopped the placebo due to the same reasons [4]. Cur-
rently, most information on arthritis medications is pro-
vided in the written format, which can be challenging
especially for people with low literacy. However, while
most health service delivery interventions are designed to
improve the family physician's ability to refer to a rheu-
matologist and prescribe medications [19-21], relatively
little has been done to improve the delivery of credible,
relevant, and user-friendly information for individuals to
make treatment decisions.
To address this care gap, we propose to develop and eval-
uate an Animated, Self-serve, Web-based Research Tool
(ANSWER) to assist people with a new RA diagnosis to
make decisions about using methotrexate. The innovative
aspect of ANSWER is its built-in storyline that illustrates
common situations that people experience when making
decisions about their treatment, and demonstrates the
attributes required for effective management of their
healthcare. Our specific objectives are to: 1) develop
ANSWER for people with early RA; and 2) assess the extent
to which ANSWER reduces people's decisional conflict,
improves their knowledge about RA, and improves their
skills of being 'effective healthcare consumers'.
Previous research
The development of ANSWER is based on the findings
from three projects funded by the Canadian Institutes of
Health Research (CIHR; http://webapps.cihr-irsc.gc.ca/
funding/Search?p_language=E&p_version=CIHR): 1) the
RA Care Gaps project [18]; 2) the ERAHSE (Early RA Help-
Seeking Experience) project; and 3) the Effective Con-
sumer project [22].
The RA Care Gaps project surveyed 1,822 patients in Brit-
ish Columbia (BC) and found that the main reasons for
not using DMARDs included a lack of physician advice
(45%), fear of side effects (26%), preference to avoid
medications (24%), and perceived lack of need (23%)
[18]. These findings were confirmed by ERAHSE using
qualitative interviews of 38 people with newly diagnosed
RA (12 months or less). The preliminary data analysis
identified common themes about challenges to making
treatment decisions or negotiating the healthcare system
[23], including: 1) incomplete discussions about benefits
and risks of treatment options during medical visits, mak-
ing it impossible to make an informed choice; 2) frustra-
tion with not being heard by the physician, resulting in
discontinuation of medical visits by some participants;
and 3) frustration with not knowing which, and how to
access, health resources even if they knew disease-related
information was available.
Another recurring theme identified in ERAHSE was the
complex interplay of factors that affected people's treat-
ment decisions. These included the disease characteristics
(e.g., insidious versus sudden onset), people's health
beliefs, their knowledge and attitudes toward RA and
treatments, and their past experience with medications
and health professionals. Underlying these factors was theBMC Medical Informatics and Decision Making 2009, 9:40 http://www.biomedcentral.com/1472-6947/9/40
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profound feeling of ambivalence that is marked, on one
hand, by an aversion to medications because of the antic-
ipated side effects, and on the other, by a fear of the poten-
tially crippling effects of an uncontrolled disease. The
circumstance in which people decided to use or not use
medications appeared to be influenced by the nature of
their symptoms in the context of daily life.
Concerns about side effects were part of the background
knowledge that many participants brought to their initial
medical consultations. It appeared that these concerns
were likely to remain unresolved if they left the doctor's
office with unanswered questions or unaddressed con-
cerns about the treatment. This might explain why those
who stayed on medications reported having good rapport
with their rheumatologists and/or family doctors, and
that they were more engaged in communicating and mak-
ing treatment decisions with their doctors. Interestingly,
health education messages, such as those that tout the
importance of starting DMARDs within a certain 'window
of opportunity' appeared to motivate some ERAHSE par-
ticipants to begin treatment. These findings highlight the
importance of good patient-physician partnerships in
people's decisions to use/continue medications, and pro-
vide the necessary context for the development of a deci-
sion-making tool that mirrors the typical challenges and
situations in which people make their treatment choices.
What are the attributes of an 'effective healthcare 
consumer'?
Most patient education initiatives aim to empower people
with arthritis to become active participants in their health-
care decisions (i.e., 'effective consumers'). The concept of
"effective consumer", developed by Tugwell et al. [22]
posits that individuals can acquire knowledge and skills
that empower them to manage their health and to become
more effective users of healthcare resources. Through
extensive interviews and collaborations with arthritis
patient groups, five essential attributes of effective health-
care consumers were indentified, including the ability to:
1) use health information; 2) clarify personal priorities for
disease management; 3) communicate with health profes-
sionals; 4) negotiate roles and take control; and 5) make
decisions and take action [22,24]. It has been argued that
these attributes can be used to guide the development of
the next generation of patient education/self-manage-
ment initiatives [25].
Another major contribution of the effective consumer
project was the EC-17 scale [24]. Unlike traditional meas-
ures in studies of self-management interventions, which
focus on RA outcomes (e.g., pain, joint counts, self-effi-
cacy, life satisfaction, coping, social function) [26], the
EC-17 evaluates the person's ability to participate in his/
her healthcare. The psychometric properties of the EC-17
are currently being tested in self-management interven-
tions [24]. In the ANSWER project, we will apply the effec-
tive consumer attributes to design the knowledge and
skills learned by the main character portrayed in the
ANSWER storyline, and will use the EC-17 scale in the
pilot evaluation.
Methods/design
ANSWER will be developed based on the rigorous criteria
outlined in the International Patient Decision Aid Stand-
ards [27,28], and through a collaboration of health
researchers, computer animation experts and trainees,
and people with RA. Using an iterative design approach,
we will create an animated decision aid for users with low
health literacy and low-to-average computer skills.
Because our main audience is people recently diagnosed
with RA, we will focus on creating scenarios that are less
threatening to the users (e.g., starting the story in the
home and work environment rather than in a hospital).
ANSWER will be structured with dual components: stories
acted by the main animated character and an interactive
decision-making component.
We will adapt Jibaja-Weiss et al.'s Edutainment Decision
Aid Model [29], which consists of three inter-linked com-
ponents: the story; the learning media; and the graphical
user interface by which the user interacts with the story
and learning media. At different points throughout the
story, the user will be required to make decisions. Deci-
sion support information (i.e., the risk and benefits of
treatment options) will be embedded in both the story
and learning media. The animated character will model
the skills necessary to be an effective consumer.
The development process of the ANSWER tool involves:
1) writing a brief interactive narrative with multiple sto-
rylines for the animated segments and content for the
learning segments; 2) refining the storyline and learning
segments; and 3) defining the linkages between the story
and the learning segments. The storyline will be based on
the ERAHSE qualitative interviews. Once the user com-
pletes the program, a tailored summary will be generated
describing his/her health information, treatment choices,
initial decisions made, and concerns about the treatments
he/she wishes to discuss with the doctor.
The decision support component will focus on the use of
methotrexate. ANSWER will be developed based on the
current systematic reviews and clinical practice guidelines
about methotrexate [30,31], including the probability for
favourable clinical outcomes and side effects. To enable
use by computer novices, we will design the graphical user
interface of the decision aid such that it resembles a com-
puter game that allows user interaction to enhance theBMC Medical Informatics and Decision Making 2009, 9:40 http://www.biomedcentral.com/1472-6947/9/40
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uptake of information. All written content and instruc-
tions will be fully narrated.
We will test the content and user interface of the ANSWER
prototype with five people from each of the following
groups: 1) rheumatologists/arthritis nurses; 2) allied
health professionals; 3) people with RA diagnosed ≤ 3
months; 4.) those with RA > 3 months. The time needed
to complete the tool will be tracked. After the testing sec-
tion, participants will be interviewed to obtain comments
about the content, presentation and user friendliness. The
tool will be refined based on the users' comments.
Pilot study
A prospective pre-post design will be used in the online
pilot study. We will invite people with RA across Canada
to participate. Eligible individuals will be those who: 1)
are diagnosed with RA; 2) are candidates for methotrexate
as indicated by their rheumatologists and have not initi-
ated treatment; and 3) have Internet access. Participants
will be recruited from two sources: 1) the Mary Pack
Arthritis Program; and 2) patient/consumer groups,
including the Canadian Arthritis Patients Alliance and
JointHealth. In addition, we will post the information on
the Arthritis Research Centre of Canada website. Individ-
uals who are interested may contact the research assistant
who will provide details about the study, screen for eligi-
bility and obtain informed consent.
Participants will receive a username and password via e-
mail to access the ANSWER testing webpage. They may
complete the program at their own pace, and may sign off
and return later. At the end of the program, ANSWER will
produce a one-page summary for the individual to discuss
with his/her rheumatologist/family physician, and then
make a decision about the treatment.
Outcome measures
Participants will be asked to complete the following meas-
ures online before and after using the ANSWER: 1) the
Decisional Conflict Scale (low literacy version; primary
outcome); 2) the EC-17 Scale; and 3) the ACREU (Arthri-
tis Community Research & Evaluation Unit) RA Knowl-
edge Questionnaire. The Decisional Conflict Scale
measures personal perceptions of uncertainty in choosing
options, factors contributing to uncertainty, and effective
decision making [32]. The low literacy version has 10
questions and three response categories. Both internal
consistency and test-retest reliability exceed 0.78. In stud-
ies of decision aids for non-RA interventions, the effect
sizes range form 0.4 to 1.2 [32-34].
The RA Knowledge Questionnaire comprises 31 items
covering seven domains: prognosis, coping strategies,
pain management, exercise, medication, joint protection,
and energy conservation [35]. The questionnaire has dem-
onstrated internal consistency (Cronbach's α = 0.76), test-
retest reliability (r = 0.91), and content and construct
validity [35]. Also, participants will complete the follow-
ing measures at baseline: 1.) Health Assessment Question-
naire (HAQ; a validated measure of health status of
people with RA); 2.) RADAI (RA Disease Activity Index);
and 3.) comorbid conditions and demographic character-
istics. The scores of HAQ and RADAI, and the comorbid
conditions will be summarized on the one-page summary
for participants.
Sample size and analysis
Based on previous before-and-after studies using the Deci-
sional Conflict Scale, we estimated a difference of 0.3 and
a standard deviation of 0.6 [32,33]. This yields a sample
size of 43 (α-level = 0.05; 90% power). Assuming that
15% of eligible participants do not complete the task and/
or the outcome measures, 51 participants will be needed.
Exploratory analysis using paired t-tests will be done to
evaluate the changes in the three outcome measures.
Descriptive analysis will be used to summarize participant
characteristics and comorbid conditions.
The ANSWER protocol has been approved by the Univer-
sity of British Columbia Behavioural Research Ethics
Board (Application number: H09-00898).
Limitations
Although the selected outcome measures will capture
changes in outcomes from the patient's perspective, we
will not be able to determine if the ANSWER affects the
physician's participation in shared decision-making, or if
it improves patient-physician communication during the
clinical visit. However, owing to the resources required to
collect data from the study participant's physician(s), it is
prudent to first demonstrate the value of this new tool for
the users in a small pilot study. Favorable results from this
study will provide the justification and background data
for a full-scale randomized controlled trial that evaluates
the effectiveness of ANSWER from the perspectives of
both patients and physicians.
Discussion
This innovative project combines the expertise from six
disciplines: health services research (LCL, CLB, DL, DS,
PT), clinical research (DL), social science (PA, SC, AFT),
information science (JM), knowledge translation (LCL,
PT, KH, JM) and digital media (GS), and three stakehold-
ers groups: patients/consumers (Canadian Arthritis
Patient Alliance, JointHealth, and Arthritis Research Cen-
tre of Canada – Consumer Advisory Board), the clinical
community (Mary Pack Arthritis Program), and a non-
profit arthritis organization (The Arthritis Society).BMC Medical Informatics and Decision Making 2009, 9:40 http://www.biomedcentral.com/1472-6947/9/40
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A multi-sector, inter-disciplinary team has been assem-
bled to create and evaluate the ANSWER. Guided by Gra-
ham's Knowledge-to-Action process [36], this knowledge
translation project will directly address one of the recom-
mendations of the 2005 Summit on Standards for Arthritis
Prevention and Care that, "Every Canadian with arthritis
must have access to accurate information and education
on arthritis that meet a defined set of criteria and are
appropriate to their age and stage of disease" [37] We
envision that the ANSWER will help accelerate the dissem-
ination of knowledge and skills necessary for people with
early RA to make informed choices about treatment and
to manage their health.
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